BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital

Visa fullständig post



Permalänk

http://hdl.handle.net/10138/312881

Citation

Kelppe , J , Thoren , H , Ristimäki , A , Haglund , C , Sorsa , T & Hagström , J 2019 , ' BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital ' , Oral Diseases , vol. 25 , no. 4 , pp. 1169-1174 . https://doi.org/10.1111/odi.13072

Titel: BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital
Författare: Kelppe, Jetta; Thoren, Hanna; Ristimäki, Ari; Haglund, Caj; Sorsa, Timo; Hagström, Jaana
Medarbetare: University of Helsinki, Department of Pathology
University of Helsinki, Department of Pathology
University of Helsinki, Department of Surgery
University of Helsinki, Department of Oral and Maxillofacial Diseases
University of Helsinki, Medicum
Datum: 2019-05
Språk: eng
Sidantal: 6
Tillhör serie: Oral Diseases
ISSN: 1354-523X
Permanenta länken (URI): http://hdl.handle.net/10138/312881
Abstrakt: Objectives We aimed to investigate BRAF V600E percentage immunohistochemically in ameloblastomas of a single institute cohort. We were interested if age, location, histological properties, or tumor recurrence depend on the BRAF status. Subjects, materials and methods We had 36 formalin-fixed, paraffin-embedded ameloblastoma tissue samples of patients treated at the Helsinki University Hospital between the years 1983-2016. Tissue sections underwent immunohistochemistry by Ventana BenchMark XT immunostainer using Ms Anti-Braf V600E (VE1) MAB. We used R 3.4.2 and RStudio 1.1.383 to conduct statistical analysis for BRAF positivity and earlier onset as well as tumor location. We used chi-squared tests and 2-by-2 table functions to determine connections between BRAF positivity and recurrence, growth pattern, and type. Results BRAF-positive tumors occurred in younger patients compared to BRAF-negative tumors (p = 0.015) and they located mostly to the mandible (p <0.001). Growth patterns were limited to two in BRAF-negative tumors when BRAF-positive tumors presented with one to four growth patterns (p = 0.02). None of the maxillary tumors showed BRAF positivity and of these, 72.2% recurred. Conclusions An immunohistochemical BRAF marker could be a beneficial tool to predict the outcome of patients with this aggressive, easily recurring tumor.
Subject: ameloblastoma
BRAF
immunohistochemistry
MUTATIONS
313 Dentistry
3126 Surgery, anesthesiology, intensive care, radiology
Licens:


Filer under denna titel

Totalt antal nerladdningar: Laddar...

Filer Storlek Format Granska
BRAF_V600E_expr ... ki_University_Hospital.pdf 901.8Kb PDF Granska/Öppna

Detta dokument registreras i samling:

Visa fullständig post